UTHRNasdaqPharmaceutical PreparationsFiscal year ends December 31

UNITED THERAPEUTICS Corp

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$543.15+10.03 (+1.88%)

Close on Oct 19, 2026

Community

Notes and questions about United Therapeutics from other investors

Discussion opens with sign-in. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Parsed from the XBRL in United Therapeutics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 2-for-1 split on Sep 23, 2009
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is UTHR.

Revenue growth2.5% · median 17.5%

Gross margin86.1% · median 79.8%

Operating margin44.4% · median 4.4%

Net margin41.6% · median 2.1%

Advertisement
300 × 250